The influence of ivabradine on the leukogram and leukocyte indexes in patients with heart failure: the results of 2 years observation
DOI:
https://doi.org/10.24959/cphj.14.1308Keywords:
heart failure, leukocyte indexes, IvabradineAbstract
Heart failure (HF) is a consequence of various heart diseases. Approximately 1%-2% of the adult population in developed countries has HF, with the prevalence rising to ≥ 10% among persons of 70 years old or older. Ivabradine is the first member of a new group of drugs, the specific heart rate-lowering agents, to be introduced into clinical practice for treating HF. But its effect on the leukogram is sill unclear. The aim of the work was to study dynamics of the leukogram and leukocyte indexes during long-term treatment with Ivabradine in patients with the heart failure syndrome of ischemic genesis. We observed of 35 patients with stable angina II-III FC (CCS) with HF II-III FC (NYHA). All patients were randomized into two groups: 14 patients received the basic therapy medicines; the rest of 21 patients (the second group) additionally received Ivabradine. The leukogram was analyzed and leukocyte indexes were calculated during 2 years of observation. Additional prescription of Ivabradine has shown the insignificant decrease of the lymphocyte count in 2 years of treatment. It has been found that the lymphocyte count increases in patients of the basic group, and, as a consequence, the indexes of ICNL, ICN/ML decrease. Thus, Ivabradine has an additional immunotropic effect for lymphocyte count, the mechanism of which is unclear and requires further research.
References
Регіональні медико-соціальні проблеми хвороб системи кровообігу. Динаміка та аналіз: Аналітично-статистичний посібник / За ред. В.М.Коваленка, В.М.Корнацького. – К.: ДУ «Національний науковий центр Інститут кардіології ім. акад. М.Д.Стражеска, 2013. – 236 с.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 // Eur. Heart J. – 2012. – Vol. 33. – P. 1787-1847.
Fox K.M., Ferrari R. // Nat. Rev. Cardiol. – 2011. – Vol. 8 (7). – P. 369-379.
Kaya Z., Leib C., Katus H.A. // Circ. Res. – 2012. – Vol. 110 (1). – P. 145-158.
McMurray J.J., Adamopoulos S., Anker S.D. et al. // Eur. Heart J. – 2012. – Vol. 33. – P. 1787-1847.
Mosterd A., Hoes A.W. // Heart. – 2007. – Vol. 93. – P. 1137-1146.
She R.C., Hammond E.H. // Cardiovasc. Pathol. – 2010. – Vol. 19 (4). – P. 99-105.
Takeda A., Taylor S.J., Taylor R.S. et al. // Cochrane Database Syst. Rev. – 2012. – Vol. 9. – P. 27-52.
Yancy C.W., Jessup M., Bozkurt B. et al. // J. Am. Coll. Cardiol. – 2013. – Vol. 62. – P. e147-e239.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
